Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $249000.0.

  • Champions Oncology's Share-based Compensation rose 266666.67% to $249000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $844000.0, marking a year-over-year decrease of 715.07%. This contributed to the annual value of $654000.0 for FY2025, which is 4150.27% down from last year.
  • Per Champions Oncology's latest filing, its Share-based Compensation stood at $249000.0 for Q4 2025, which was up 266666.67% from $208000.0 recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Share-based Compensation registered a high of $423000.0 during Q3 2023, and its lowest value of $9000.0 during Q4 2024.
  • Over the past 5 years, Champions Oncology's median Share-based Compensation value was $220000.0 (recorded in 2021), while the average stood at $219900.0.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 8301.89% in 2024, then surged by 266666.67% in 2025.
  • Over the past 5 years, Champions Oncology's Share-based Compensation (Quarter) stood at $134000.0 in 2021, then dropped by 11.19% to $119000.0 in 2022, then tumbled by 55.46% to $53000.0 in 2023, then crashed by 83.02% to $9000.0 in 2024, then skyrocketed by 2666.67% to $249000.0 in 2025.
  • Its Share-based Compensation was $249000.0 in Q4 2025, compared to $208000.0 in Q3 2025 and $131000.0 in Q2 2025.